Navigation Links
Successful Field-Trial Remediation of 1,2-DCA and VC Contaminated Groundwater in Northern Italy
Date:6/3/2009

Gruppo TRS Selects Adventus EHC® Enhanced Natural Attenuation Biotechnology as Demonstrably Superior to Alternatives

New York, NY (Vocus) June 3, 2009 -- The Adventus Group, an international remediation biotechnology enterprise for treatment of contaminated soil, sediment and groundwater environments, is proud to announce that laboratory and field tests recently conducted in Italy resulted in its patented EHC® In Situ Chemical Reduction (ISCR) biotechnology being selected over RegenOx® (Regenesis) In Situ Chemical Oxidation (ISCO) for its ability to meet vendor claims and client expectations for an effective, cost-efficient remedial strategy. The environmental engineering firm of Gruppo TRS conducted extensive testing, and presented their findings at the BOSICON 2009 International Conference on Remediation of Polluted Sites, held May 13-15 in Rome, Italy.

ABSTRACT

The presentation described rigorous laboratory and field tests conducted to select and optimize an in situ remedial design for a large, complex site located inside an operating petrochemical plant in Northern Italy. The subsurface environment at the site is impacted by 1,2-dichloroethane (1,2-DCA) and vinyl chloride (VC) about 300,000 and 500 ?g/L in groundwater, respectively. Knowing the general persistence of 1,2-DCA in the environment, initial laboratory tests evaluated various remedial technologies: two different chemical oxidants (ISCO) and biochemical anaerobic reduction (ISCR). Of the two oxidants tested, only the activated persulfate was effective; RegenOx showed no activity whatsoever. Although the ISCR reactions required a longer treatment time, both 1,2-DCA and VC were completely removed in less than sixty days, without the accumulation of dead-end catabolites.

The use of EHC for ISCR was subsequently chosen for field-scale test, considering its minimal geochemical impact on soil and groundwater conditions. The initial field test area was ca. 50 m2 and the total volume of saturated soil treated was ca. 700 m3. A total of 6,300 kg of EHC amendment was injected through nine injection points using direct-push technology. Groundwater monitoring from four proximal observation wells showed a widespread and sustained reduction in redox (Eh -150 mV to -450 mV) and, most significantly, within ca. 9 months the groundwater concentrations of both 1,2-DCA and VC were reduced from ca. 800,000 ?g/L to in to below the regulatory treatment standards (SSTL) of 1,500 ?g/L, with two of the monitoring wells containing < 10 ?g/L 1,2-DCA.

CONCLUSIONS

Design of full-scale site remediation using the EHC ISCR technology is being completed. Simultaneously, continued monitoring of the field site t time on-going to verify the effective reagent life and document lack of “rebound” which is typical for many other remedial technologies. Full scale implementation will employ 600 to 700 tonnes of EHC to treat an area measuring 7,000 m2 and is planned for 2009 through 2011

A complete copy of the Report is available via PDF at http://www.adventusgroup.com/library/presentations.shtml

More information on Gruppo TRS is available via their website at
http://www.gruppo-trs.it/portfolio/pubblico/menu_descrizione.asp?categoria=134

About The Adventus Group – Environmental Biotechnologies for the 21st Century
ADVENTUS provides a growing portfolio of leading environmental remediation technologies, including patented offerings from Adventus Americas Inc., and EnviroMetal Technologies Inc. Our business model supports site owners, environmental engineers, consultants, regulators, and the academic community by providing unbiased design, and selection of the most cost-effective remediation strategies. Our proprietary portfolio includes:

Creators of the World’s First In Situ Chemical Reduction (ISCR) technologies:
-   DARAMEND® for soils, sludges and sediments;
-   EHC® portfolio of injectable amendments for groundwater;
-   EHC® -A liquid formulation for wells and other networks;
-   EHC® -M for immobilization of soluble metal impacts;
-   A-SOX™ canister delivery system;
-   ZVI PRBs and related groundwater treatment innovations;
-   ZVI-Clay for in situ source zone treatment;
-   EHC-O® oxygen releasing compound for in situ hydrocarbon treatment;
-   O-SOX™ canister delivery system;
-   ISGS™ in situ geochemical stabilization of DNAPL;
-   AquaBlok+™ for capping and treatment of impacted sediments;
-   HoleBlok+™ down-well, low-permeability sealant;
-   mGCW™ microbiologically enhanced Groundwater Circulation Wells;
-   Modeling Services for optimization of remedial designs and strategies.

The ADVENTUS scientific team is a recognized practice leader, with more than 500 conference Abstracts and a cumulative total of over 2,500 technical publications within the industry. Through April 2009, we have successfully treated over 5,000,000 metric tons of soil impacted by hazardous wastes, and millions of gallons of groundwater at over 1,000 sites around the globe. We offer the only codified performance warranties in the vendor community, designed to risk-share with you in a fair and deliberative manner. The Adventus family of companies is always seeking strategic partnerships with complementary remediation biotechnologies, and qualified international licensees in numerous countries.

###

Read the full story at http://www.prweb.com/releases/bioremediationtechnology/contaminatedgroundwater/prweb2489974.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Orthocrat Announces Successful Implementation of TraumaCad at UPMC Mercy
2. Successful Phase I/II Clinical Trial Results From Cancer Patients Treated With Anti-Cancer Drug From Axelar AB
3. Symphony Medical Announces First Patient Successfully Treated With Novel Congestive Heart Failure Therapy
4. Zenobia Therapeutics Successfully Completes Initial Phase of Its Service Agreement With Syntonix Pharmaceuticals
5. VeraSun Energy Selects Valero as Successful Bidder for Seven Facilities
6. Bavarian Nordic Has Essentially Agreed a Pathway for the Licensure of IMVAMUNE(R) With the FDA After Successful End of Phase II Meeting
7. EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology
8. Endo Pharmaceuticals Successfully Completes Tender Offer for Shares of Indevus Pharmaceuticals and Announces Subsequent Offering Period
9. DiFUSION Technologies Completes Successful Testing of Antimicrobial Spinal Implant
10. WaferGens SmartChip(TM) System Performance Successfully Demonstrated in Initial Phase of Alpha Testing Program
11. GlaxoSmithKline Successfully Completes Tender Offer for Shares of Genelabs Technologies, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Successful Field-Trial Remediation of 1,2-DCA and VC Contaminated Groundwater in Northern Italy
(Date:2/27/2017)... ... ... The Catalyst Midwest premix manufacturing facility has been certified as organic, ... label organic services. , The first organic product is Organic 18 Percent Layer Feed, ... Marketing, which owns the facility. , Catalyst already has received the Safe Feed/Safe ...
(Date:2/24/2017)... Calif. (PRWEB) , ... February 24, 2017 , ... Chef ... and wine scene. Making stops in several cities, she gained a number of ... adventure began in Stellenbosch, a town in South Africa’s Western Cape province. It ...
(Date:2/24/2017)... Blood Corporation (NYSE: CO ) ("CCBC" or ... laboratory testing, hematopoietic stem cell processing and stem cell ... the third quarter and first nine months of fiscal ... Quarter of Fiscal 2017 Highlights Revenues ... 18.6% to RMB200.9 million ($28.9 million). ...
(Date:2/23/2017)... NEW YORK , Feb. 23, ... , a leading digital health company, and ... of telemedicine and remote patient monitoring, announce they ... reimbursements.  DN Telehealth maximizes collaboration ... real-time, extending consultations beyond a physical clinical setting ...
Breaking Biology Technology:
(Date:2/10/2017)... Research and Markets has announced ... - Scientific and Commercial Aspects" to their offering. ... Biomarkers ... with therapy for selection of treatment as well for monitoring ... of disease in modern medicine. Biochip/microarray technologies and next generation ...
(Date:2/8/2017)... NEW YORK , Feb. 7, 2017 Report ... ... and should reach $11.4 billion by 2021, growing at a ... Report Includes - An overview of the global markets for ... from 2015, estimates for 2016, and projections of compound annual ...
(Date:2/7/2017)... , Feb. 7, 2017 Zimmer Biomet ... in musculoskeletal healthcare, will present at the LEERINK Partners ... York Palace Hotel on Wednesday, February 15, 2017 at ... webcast of the presentation can be accessed at ... following the conference via Zimmer Biomet,s Investor Relations website ...
Breaking Biology News(10 mins):